Artivion Announces U.S. FDA Approval of the AMDS Hybrid Prosthesis

Artivion Seeks To Tap $150 Million US Market Opportunity With FDA Approval - Artivion (NYSE:AORT)

Artivion secured FDA PMA approval for AMDS, removing IRB hurdles and expanding access for acute aortic dissection patients.